Lantheus Inc. (LNTH)
Lantheus Inc. (LNTH) Stock Price, Analysis & Data
| Precio de compra | n/a |
| Capitalización de mercado | 6.54B |
| Ingresos (TTM) | 1.56B |
| Beneficio neto (TTM) | 275.3M |
| Beta | -0.03 |
| EPS (TTM) | 4.15 |
| Ratio PER (TTM) | 24.16 |
| Adelante PE | 15.85 |
| P/B (TTM) | 4.99 |
| P/S (TTM) | 4.20 |
| Earnings Date | Nov 5, 2026 |
| Precio de venta | n/a |
| Volumen | 2,022,484 |
| Volumen medio (20D) | 1,333,009 |
| Abierto | 100.93 |
| Anterior Cerrar | 100.91 |
| Rango del día | 100.15 - 100.96 |
| Rango de 52 semanas | 49.67 - 111.86 |
| analista | n/a |
| Precio objetivo | n/a |
| Dividendos | n/a |
| Fecha ex dividendo | n/a |
Acerca de LNTH
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide. The company offers DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, a...
Desempeño financiero
En 2025, los ingresos de Lantheus fueron 1.54B, un aumento de 0.5% en comparación con 1.53B del año anterior. Las ganancias fueron 233.56M, una disminución de -25.25%.
Estados financierosSorpresa de resultados
Los analistas proyectan ingresos de ... Actualizar
2 semanas hace · Simply Wall St.
Lantheus (LNTH) Agrees To Join Curium In Radiopharmaceuticals DealCurium has entered into a definitive agreement to acquire Lantheus Holdings (NasdaqGM:LNTH) in a transaction that will combine their radiopharmaceutical businesses. The deal was unanimously approved b...
